Mersana Therapeutics Valuation
| MRSN Stock | USD 2.00 0.04 1.96% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Mersana Therapeutics secures a last-minute Real Value of $1.83 per share. The latest price of the firm is $2.0. Our model forecasts the value of Mersana Therapeutics from analyzing the firm fundamentals such as Current Valuation of 128.34 M, return on equity of -2.13, and Profit Margin of (2.14) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Mersana Therapeutics' valuation include:
Price Book 240.2356 | Enterprise Value 128.3 M | Enterprise Value Ebitda (2.20) | Price Sales 7.2339 | Enterprise Value Revenue 3.684 |
Overvalued
Today
Please note that Mersana Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Mersana Therapeutics is based on 3 months time horizon. Increasing Mersana Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Mersana Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mersana Stock. However, Mersana Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.0 | Real 1.83 | Target 2.0 | Hype 1.91 | Naive 1.75 |
The intrinsic value of Mersana Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mersana Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mersana Therapeutics helps investors to forecast how Mersana stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mersana Therapeutics more accurately as focusing exclusively on Mersana Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Mersana Therapeutics' intrinsic value based on its ongoing forecasts of Mersana Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Mersana Therapeutics' closest peers.
Mersana Therapeutics Cash |
|
Mersana Valuation Trend
Knowing Mersana Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Mersana Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Mersana Therapeutics Total Value Analysis
Mersana Therapeutics is now projected to have valuation of 128.34 M with market capitalization of 252.01 M, debt of 33.83 M, and cash on hands of 225.13 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Mersana Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
128.34 M | 252.01 M | 33.83 M | 225.13 M |
Mersana Therapeutics Investor Information
About 95.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.6. Mersana Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Mersana Therapeutics' liquidity, profitability, solvency, and operating efficiency, Mersana Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Mersana Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mersana Therapeutics has an asset utilization ratio of 16.3 percent. This suggests that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Mersana Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Mersana Therapeutics Ownership Allocation
Mersana Therapeutics maintains a total of 123.53 Million outstanding shares. The majority of Mersana Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mersana Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mersana Therapeutics. Please pay attention to any change in the institutional holdings of Mersana Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Mersana Therapeutics Profitability Analysis
The company reported the previous year's revenue of 36.85 M. Net Loss for the year was (171.67 M) with loss before overhead, payroll, taxes, and interest of (146.8 M).About Mersana Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Mersana Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Mersana Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Mersana Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Mersana Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mersana Therapeutics. We calculate exposure to Mersana Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mersana Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -111.4 M | -105.8 M | |
| Pretax Profit Margin | (4.66) | (4.89) | |
| Operating Profit Margin | (4.64) | (4.87) | |
| Net Loss | (4.66) | (4.89) | |
| Gross Profit Margin | (3.02) | (3.17) |
Mersana Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 116.1 M |
Mersana Therapeutics Current Valuation Indicators
Mersana Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Mersana Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Mersana Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Mersana Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Mersana Therapeutics' worth.When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.286 | Quarterly Revenue Growth 0.637 | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.